Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Quarterly Earnings Results, Beats Expectations By $0.91 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) announced its quarterly earnings results on Tuesday. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.91, Briefing.com reports. The firm had revenue of $40.56 million for the quarter, compared to the consensus estimate of $35.00 million. During the same period in the prior year, the business earned ($1.07) earnings per share.

Zentalis Pharmaceuticals Trading Up 1.0 %

Shares of ZNTL stock opened at $12.43 on Thursday. The firm’s fifty day moving average price is $13.70 and its two-hundred day moving average price is $13.43. Zentalis Pharmaceuticals has a 1 year low of $9.56 and a 1 year high of $31.46. The firm has a market capitalization of $882.65 million, a P/E ratio of -2.74 and a beta of 1.82.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. HC Wainwright dropped their price target on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday. Stifel Nicolaus reduced their target price on Zentalis Pharmaceuticals from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Wedbush boosted their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $37.14.

Insider Activity

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the transaction, the chief financial officer now directly owns 451,449 shares in the company, valued at $5,164,576.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.10% of the stock is owned by corporate insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.